Daiichi Sankyo Company, Limited (TYO:4568)
Japan · Delayed Price · Currency is JPY | Market Cap | 6.35T |
| Revenue (ttm) | 1.98T |
| Net Income (ttm) | 279.90B |
| Shares Out | 1.85B |
| EPS (ttm) | 149.68 |
| PE Ratio | 22.94 |
| Forward PE | 16.13 |
| Dividend | 78.00 (2.27%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 3,326,100 |
| Average Volume | 6,009,225 |
| Open | 3,420.00 |
| Previous Close | 3,411.00 |
| Day's Range | 3,418.00 - 3,457.00 |
| 52-Week Range | 3,036.00 - 4,564.00 |
| Beta | -0.25 |
| RSI | 47.39 |
| Earnings Date | Jan 30, 2026 |
About Daiichi Sankyo Company
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation for the treatment ... [Read more]
Financial Performance
In 2024, Daiichi Sankyo Company's revenue was 1.89 trillion, an increase of 17.77% compared to the previous year's 1.60 trillion. Earnings were 295.76 billion, an increase of 47.34%.
Financial StatementsNews
AstraZeneca, Daiichi Sankyo's ENHERTU Wins FDA's Breakthrough Therapy Designation In US
(RTTNews) - AstraZeneca PLC (AZN), along with pharmaceutical company Daiichi Sankyo, Monday announced that fam-trastuzumab deruxtecan-nxki, sold under the brand name ENHERTU, has been granted the Food...
ENHERTU Gets Tenth Breakthrough Therapy Designation, Launches Phase 3 Trial In Endometrial Cancer
(RTTNews) - Daiichi Sankyo Co., Ltd (4568.T) and AstraZeneca Plc (AZN) announced that the U.S. FDA has granted Breakthrough Therapy Designation to ENHERTU as post-neoadjuvant therapy for adult patient...
Daiichi Sankyo Company, Limited (DSNKY) Discusses Oncology Pipeline Advances and Phase III Clinical Updates at Science and Technology Day Transcript
Daiichi Sankyo Company, Limited (DSNKY) Discusses Oncology Pipeline Advances and Phase III Clinical Updates at Science and Technology Day December 15, 2025...
AstraZeneca : ENHERTU Combination Approved In US For 1st-Line HER2-Positive Metastatic Breast Cancer
(RTTNews) - AstraZeneca and Daiichi Sankyo's ENHERTU (fam-trastuzumab deruxtecan-nxki), in combination with pertuzumab, has received approval in the United States for the first-line treatment of adult...
Daiichi Sankyo Company, Limited (DSNKY) Discusses Oncology Pipeline Advances and Phase III Clinical Updates at Science and Technology Day - Slideshow
2025-12-15. The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with this event.
AstraZeneca (AZN) and Daiichi Sankyo's Enhertu Combo Gains FDA Approval
AstraZeneca (AZN) and Daiichi Sankyo's Enhertu Combo Gains FDA Approval
US FDA approves Daiichi Sankyo's therapy to treat breast cancer
The U.S. Food and Drug Administration has approved Daiichi Sankyo's therapy in combination with Roche's drug for the first-line treatment of patients with a type of breast cancer, the regulator said o...
Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research
Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research and development programs SEOUL, South Korea , Dec. 15, 202...
Daiichi Sankyo: Pressing The ADC Case Further, Not Being Felt By The Market
Daiichi Sankyo Showcases Strength of Industry-Leading ADC Portfolio with Latest Research Updates from Five Landmark Breast Cancer Trials at SABCS
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new breast cancer clinical research across its DXd antibody drug conjugate (ADC) portfolio from more than 30 abstr...
Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--On December 2, the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit) reversed a decision from the U.S. District Court for the Eastern Di...
Daiichi Sankyo partnering with General Proximity on oncology targets
General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC™ Platform
- The collaboration will leverage General Proximity's OmniTAC™ platform to identify and advance next generation induced proximity agents for high value oncology targets. - Induced proximity medicines,...
DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patient has been dosed in a first-in-human phase 1 trial evaluating DS3610 in patients with advanced, metastatic or unresectable solid tumors. D...
Daiichi Sankyo Company, Limited (DSNKY) Q2 FY2025 Earnings Call Transcript
Q2 2026 Daiichi Sankyo Co Ltd Earnings Presentation Transcript
Q2 2026 Daiichi Sankyo Co Ltd Earnings Presentation Transcript
Daiichi Sankyo (DSKYF) Reports Strong 1H Financial Results
Daiichi Sankyo (DSKYF) Reports Strong 1H Financial Results
Daiichi Sankyo GAAP EPS of ¥70.52, revenue of ¥975.35B; updates FY outlook
Daiichi Sankyo Company, Limited 2026 Q2 - Results - Earnings Call Presentation
Daiichi Sankyo H1 Earnings Down, Cuts FY Earnings View, Lifts Revenue Forecast; Stock Down
(RTTNews) - Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) on Friday trimmed its earnings forecast for full-year ending March 31, 2026, after reporting weak profit in its first half. Howe...
Daiichi Sankyo Co Ltd (TSE:4568) Q2 2026 Earnings Report Preview: What To Expect
Daiichi Sankyo Co Ltd (TSE:4568) Q2 2026 Earnings Report Preview: What To Expect
Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials and Additional Data Across Industry-Leading ADC Portfolio at ESMO
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio with four late-breaking presentations...
AstraZeneca, Daiichi Sankyo succeed in late-stage breast cancer study
AstraZeneca & Daiichi Sankyo's Datroway shows improved survival in late-stage triple-negative breast cancer trial. Read more here.